They are exploring the complex relationship between hormone therapy and neurodegenerative diseases.

Positive results of pyrotinib and nab-paclitaxel in HER2+ breast cancer

Preliminary data from a phase II study show that this combination benefits patients with metastatic disease and prior treatment with trastuzumab. + read more

Benefits of Abemaciclib and Fulvestrant in HR+/Her2-Advanced Breast Cancer

The combination provides a better efficacy-to-toxicity ratio than other cyclin-dependent kinase inhibitors. + read more

HR+ breast cancer patients can stop endocrine therapy and undergo procedures to become pregnant

The percentage of women who had a recurrence of breast cancer within three years was similar in the group who interrupted endocrine therapy and underwent this procedure to increase ovarian response (9.7%) compared with those who did not undergo ovarian stimulation (8.7%). + read more

“Avoidable factors include hormone replacement therapy, overweight and obesity, and a sedentary lifestyle.”

At A Pie de Consulta we visit doctors’ work centres to learn more about their daily lives. We talk to them to find out how they do their job, what their challenges and demands are in times like these. + read more

New Combination With Hormonal Therapy Trastuzumab and Palbociclib Reduces Risk of Breast Cancer Progression by 48%

SOLTI presented the PATRICIA study, the first study to perform molecular selection of patients with advanced breast cancer. The results were very positive, as it demonstrated that the prognostic value allows to propose new, less toxic treatment alternatives, with greater efficacy and better tolerability. + read more

The NCAPH gene is involved in the prognosis and development of breast cancer.

A study conducted by the Complutense University of Madrid (UCM) and the CSIC demonstrates the importance of the NCAPH gene in the progression of luminal A breast cancer, confirming its involvement in the development of the disease. + read more